Hematology Frontier

Graft-versus-host disease (GVHD) remains one of the most severe complications following hematopoietic stem cell transplantation. Among its manifestations, acute gastrointestinal GVHD is particularly challenging to manage. Despite standard therapies, a substantial proportion of patients fail treatment, and no approved therapeutic options currently exist for those with refractory disease, representing a major unmet medical need.

Amid the vibrant renewal of spring, the 2026 CACA Western Integrated Oncology Conference was grandly convened in Chengdu, Sichuan. The meeting brought together leading oncology experts from across China to explore the frontiers of precision oncology and advance integrated, whole-course cancer care.

Amid the vibrant renewal of spring, the 2026 CACA Western Integrated Oncology Conference was grandly convened in Chengdu, Sichuan. The meeting brought together leading oncology experts from across China to explore the frontiers of precision oncology and advance integrated, whole-course cancer care.

Academic progress begins with debate and matures through consensus. As a cornerstone therapy for hematologic diseases, hematopoietic stem cell transplantation (HSCT) continues to face numerous unresolved controversies and clinical dilemmas. Centered on the theme “The Art of Transplantation,” the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT 2026) brought together leading experts from around the world to discuss technological innovation and future directions in transplantation medicine.

To further promote the expansion, equitable distribution, and accessibility of high-quality cancer care resources, and to enhance the academic and clinical capabilities of oncology care in western China and at the grassroots level, the 2026 CACA Western Integrated Oncology Conference was successfully held in Chengdu on April 18, 2026. The conference provided a high-level platform for academic exchange and translational collaboration in oncology.

Amid the vibrant renewal of spring, the 2026 CACA Western Integrated Oncology Conference was grandly convened in Chengdu, Sichuan. The meeting brought together leading oncology experts from across China to explore the frontiers of precision oncology and advance the practice of integrated, whole-course cancer care.

To further expand access to high-quality cancer care resources, promote equitable distribution, and enhance the academic and clinical capacity of oncology care in western China and at the grassroots level, the 2026 CACA Western Integrated Oncology Conference was successfully held in Chengdu on April 18, 2026. The conference provided a high-level platform for academic exchange and translational collaboration in oncology.

The diagnosis and treatment of hematologic diseases remain a global challenge. In recent years, with the rapid emergence of innovative therapies such as chimeric antigen receptor T-cell (CAR-T) therapy and the deepening understanding of hematologic disorders, the field has entered a new era.